BNTC

Benitec Biopharma Inc. [BNTC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BNTC Stock Summary

Top 10 Correlated ETFs

BNTC

Top 10 Correlated Stocks

BNTC

In the News

BNTC Financial details

Company Rating
-
Market Cap
14.26M
Income
-21.87M
Revenue
61K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.34
Forward P/E
-
PEG
0.05
P/S
108.73
P/B
0.31
P/C
-
P/FCF
-0.44
Quick Ratio
5.72
Current Ratio
5.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-10.94
EPS next Y
-
EPS next Q
-
EPS this Y
-63.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-63.33%
Revenue Q/Q
-
EPS Q/Q
-4.35%
-
-
-
-
SMA20
14.29%
SMA50
33.33%
SMA100
6.67%
Inst Own
-
Inst Trans
-
ROA
-75%
ROE
-224%
ROC
-0.9%
Gross Margin
241%
Oper. Margin
-27167%
Profit Margin
-27049%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.86-9.01
52W High
+74.89%
52W Low
+1474%
RSI
61
Rel Volume
1.27
Avg Volume
17.39K
Volume
22.11K
Perf Week
0.58%
Perf Month
13.07%
Perf Quarter
16.25%
Perf Half Y
15.82%
-
-
-
-
Beta
1.024
-
-
Volatility
0.32%, 1.03%
Prev Close
-4.72%
Price
15.74
Change
0.61%

Something similar

Top by Market Cap
AVGO
NVD.DE
CMC.DE
META
VOO
Top Correlated ETFs
GILI.L
BNDX
MLN
FLMB
VIGB.DE
Top Correlated Stocks
MCC.BR
0Z1Q.L
MANU
CKHGY
NBG6.DE
Similar Market Cap
GDR.L
FLXG.DE
FXP
8280.HK
EFBI

Company Profile

Healthcare Biotechnology
  • Volume Average 17.39K
  • Market Capitalization 14.26M
  • Employee 16
  • CEO Dr. Jerel A. Banks M.D., Ph.D.
  • Headquarters Hayward,CA,US
  • IPO Date 2014-06-24
  • Website https://benitec.com

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.